Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pedro Pablo Guerra"'
Autor:
Kirenia Camacho Sosa, Mayra Ramos Suzarte, Carmen Elena Viada González, Elia Nenínger Vinageras, Eduardo Rafael Santiesteban Álvarez, Maurenis Hernández Pérez, Yoanna Ivette Flores Vega, Saylin Alfonso Alemán, Ramón Alberto Ortiz Carrodeguas, Soraida Candida Acosta Brooks, Pedro Pablo Guerra Chaviano, Ivis Mendoza Hernández, Tania Crombet Ramos, Agustín Lage Dávila
Publikováno v:
Revista Cubana de Medicina Militar, Vol 52, Iss 3, Pp e02303004-e02303004 (2023)
Introduction: The response to therapies in advanced lung cancer could be related to certain prognostic factors such as inflammatory indices. Objective: To evaluate the efficacy of the humanized monoclonal antibody nimotuzumab in patients with advance
Externí odkaz:
https://doaj.org/article/e192693e6d24410daf2fcef4ca8c7838
Autor:
Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Olivia Fernández-Medina, Anet Valdés-Zayas, Guang-Wu Chen, Luís Herrera-Martínez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo
Publikováno v:
The Lancet Regional Health. Americas, Vol 4, Iss , Pp 100079- (2021)
Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID
Externí odkaz:
https://doaj.org/article/54ac04bcc70849c995125a973cce9fdb
Autor:
Ana de la Torre, Julio Hernandez, Ramón Ortiz, Meylán Cepeda, Kirenia Perez, Adriana Car, Carmen Viada, Darién Toledo, Pedro Pablo Guerra, Elena García, Migdacelys Arboláez, Luis E Fernandez
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2012, Iss 6, Pp 151-157 (2012)
Externí odkaz:
https://doaj.org/article/6a2a92f76d1f4ab6b75dc5f3b68e4d32
Autor:
Vicente Verez-Bencomo, Kalet Leon-Monzon, Yaima Zuniga-Rosales, Yanet Jerez-Barcelo, Yury Valdés-Balbín, Carmen Valenzuela-Silva, Marianniz Diaz-Hernandez, Yanet Climent-Ruiz, Juliet Enriquez-Puertas, Maria de los A. Garcia-Garcia, Delia Porto-Gonzalez, Raul Gonzalez-Mugica, Dagmar García-Rivera, Belinda Sanchez-Ramirez, Rocmira Perez-Nicado, Guang-Wu Chen, Pedro Pablo Guerra-Chaviano, Luis Herrera Martinez, Mireida Rodriguez-Acosta, Arturo Chang-Monteagudo, Tays Hernandez-Garcia, Rolando Ochoa-Azze, Rinaldo Puga-Gomez, Luis Dairon Rodríguez-Prieto, Ivette Orosa-Vazquez, Laura Ruiz-Villegas, Yenisey Triana-Marrero, Enrique Noa-Romero, Beatriz Marcheco-Teruel, Consuelo Macías-Abraham, Laura M. Rodríguez-Noda
We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excelle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49b54584eb53e0bda49ce6494529dce
https://doi.org/10.1101/2021.02.22.21252091
https://doi.org/10.1101/2021.02.22.21252091
Autor:
Delia Porto-Gonzalez, Dagmar García-Rivera, Laura M. Rodríguez-Noda, Marianniz Diaz-Hernandez, Yanet Climent-Ruiz, Vicente Verez-Bencomo, Mireida Rodriguez-Acosta, Enrique Noa-Romero, Belinda Sanchez-Ramirez, Arturo Chang-Monteagudo, Pedro Pablo Guerra-Chaviano, Rolando Ochoa-Azze, Carmen Valenzuela-Silva, Olivia Fernández-Medina, Anet Valdes-Zayas, Yanet Jerez-Barcelo, Tays Hernandez-Garcia, Rocmira Perez-Nicado, Beatriz Marcheco-Teruel, Yenisey Triana-Marrero, Guang-Wu Chen, Laura Ruiz-Villegas, Rinaldo Puga-Gomez, Luis Dairon Rodríguez-Prieto, Maria de los A. Garcia-Garcia, Consuelo Macías-Abraham, Yury Valdés-Balbín, Juliet Enriquez-Puertas, Ivette Orosa-Vazquez, Yaíma Zúñiga-Rosales, Luis Herrera-Martínez
Publikováno v:
The Lancet Regional Health. Americas, Vol 4, Iss, Pp 100079-(2021)
Lancet Regional Health. Americas
Lancet Regional Health. Americas
Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469c1a80321831634d0a584123ac6c00
https://doi.org/10.1016/j.lana.2021.100079
https://doi.org/10.1016/j.lana.2021.100079
Autor:
Centro de Inmunología Molecular, La Habana, Cuba, Elia Neninger, Saily Alfonso, Elena García, Centro Nacional Coordinador de Ensayos Clínicos, La Habana, Cuba., Eduardo Santiesteban, Ana María Vázquez, Amparo Macías, Ivis Mendoza, Pedro Pablo Guerra, M. Hernandez, Carmen Viada, Leslie Pérez, Martha Fors
Publikováno v:
Bionatura. 1:13-19
Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death, breast cancer is the second leading cause of death and colorectal cancer is the third leading cause of death. The 1E10 anti-idiotype vaccine is a new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac9f0789f0984db411c5750312dae998
https://doi.org/10.21931/rb/2016.01.01.4
https://doi.org/10.21931/rb/2016.01.01.4
Autor:
Elena García, Ramón Ortiz, Ana María Vázquez, Ana María Hernández, Ivis Mendoza, Zuyen Gonzalez, Anet Valdes-Zayas, Darien Toledo, Carmen Viada, Amparo Macías, Zaima Mazorra, Rolando Pérez, Meylan Cepeda, Fernando Areces, Kirenia Perez, Eduardo Santiesteban, Eric Chong, Ana de la Torre, Tania Crombet, Yoanna I. Flores, M. Hernandez, Pedro Pablo Guerra, Saily Alfonso
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(14)
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenance for patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89396536f30b3a2c4c2790544c154ac6
https://pubmed.ncbi.nlm.nih.gov/24788102
https://pubmed.ncbi.nlm.nih.gov/24788102
Autor:
Amparo Macías, M. Hernandez, Elia Neninger, Anet Valdes, Yoana Flores, Ivis Mendoza, Rosa Maria Amador, Ramón Ortiz, Eduardo Santiesteban, Mayte Robaina, Tania Crombet, Ana María Vázquez, Soraida Acosta, Pedro Pablo Guerra
Publikováno v:
Journal of Clinical Oncology. 32:TPS3111-TPS3111
TPS3111 Background: Despite extensive research in NSCLC treatment, overall survival remains insufficient. Immunotherapy has become a viable treatment to help the immune system to control or elimina...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c744fbf116e5338b989e136c49f7f8e
https://doi.org/10.1200/jco.2014.32.15_suppl.tps3111
https://doi.org/10.1200/jco.2014.32.15_suppl.tps3111